Zydus

Hillary win may pose pricing challenges for pharma cos: Report

A Democrat sweep in US polls may pose even greater pricing challenges for the pharma industry and pave the way for tighter pricing regulations for both brand name and generic drugs, according to a report.

Cadila Healthcare Q3 profit rises 52% to Rs 282 cr

Drug firm Cadila Healthcare reported a 52 percent rise in its consolidated net profit to Rs 281.91 crore for the third quarter ended 31 December 2014 on back of robust sales.

Pharma sector registers single digit growth in 2013; regulators increase scrutiny

The Indian pharma sector, estimated to be around Rs 1.5 lakh crore, recorded single digit growth for the first time in several years on account of deeper price cuts under pricing policy and selective boycott of companies by the retailers.

Zydus gets FDA tentative nod to market anti-diabetic tablets in US

According to IMS health the estimated sales in 2014 for Glipizide ER tablets is $90.1 million

Bitter pill to swallow: Price cut to hit drug makers' profitability

Last week, the National Pharmaceutical Pricing Authority (NPPA) announced that it plans to bring an additional 50 drugs belonging to the cardiovascular and anti-diabetic segment under price control.